Marc Richardson, MD
Ophthalmology · Flowood, MSNPI 1629418066
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,317 of the $6,129 with a category attached, or 86.8%. Alcon accounts for 65.3% of it on its own, with 21 other manufacturers making up the rest.
Across 213 payments — averaging $28.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$4K
- AbbVie$497
- Bausch & Lomb Americas Inc.$373
- Oyster Point Pharma, Inc.$253
- Bausch & Lomb, A Division Of Bausch Health US, LLC$167
- Aerie Pharmaceuticals, Inc.$124
- plus $712 from 16 others
What the payments were for
- Travel & lodging$77213%
- Food & beverage$5,31787%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 99 | $4,003 |
| AbbVie(2 entities) | 27 | $497 |
| Bausch & Lomb Americas Inc. | 24 | $373 |
| Oyster Point Pharma, Inc. | 11 | $253 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $167 |
| Aerie Pharmaceuticals, Inc. | 7 | $124 |
| Mallinckrodt Hospital Products Inc. | 4 | $97 |
| Thea Pharma Inc. | 4 | $78 |
| Sun Pharmaceutical Industries Inc. | 4 | $72 |
| Ivantis, Inc | 4 | $69 |
| Omeros Corporation | 1 | $57 |
| Biotissue Holdings Inc. | 3 | $53 |
| Glaukos Corporation | 3 | $53 |
| Ocular Therapeutix, Inc. | 2 | $45 |
| Tarsus Pharmaceuticals, Inc. | 2 | $43 |
| Kala Pharmaceuticals, Inc. | 3 | $40 |
| Eyepoint US, Inc. | 1 | $20 |
| Sight Sciences, Inc. | 1 | $18 |
| Amgen | 1 | $18 |
| Novartis | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
| NEW World Medical,inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$421
- DAILIES$376
- AcrySof IQ PanOptix$255
- Clareon PanOptix Pro$139
- AcrySof IQ PanOptix UV IOL$131
- Unity$128
How this compares
$6,129 in reported general payments places this provider in the 85th percentile of 150 ophthalmology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 79 | $45,417 |
| RestasisCyclosporine | 26 | $26,451 |
| XiidraLifitegrast | 25 | $23,186 |
| Prednisolone Acetate | 207 | $12,727 |
| TyrvayaVarenicline Tartrate | 16 | $10,030 |
| RhopressaNetarsudil Mesylate | 26 | $8,143 |
| Latanoprost | 997 | $7,531 |
| Travoprost | 29 | $6,709 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $6,246 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 22 | $5,423 |
| Ketorolac Tromethamine | 191 | $5,366 |
| VyzultaLatanoprostene Bunod | 12 | $4,793 |
| MoxifloxacinMoxifloxacin Hcl | 188 | $3,986 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 234 | $3,893 |
| Timolol Maleate | 200 | $2,139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $497 | $78,114121 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $373 | $27,98037 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $253 | $10,03016 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $124 | $8,14326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 150 ophthalmology providers in Mississippi.
Other ophthalmology in Flowood
- Leslie AdenFlowood$38K
- Kiper NelsonHattiesburg$234K
- John ParkerTupelo$72K
- Joseph ChildsTupelo$42K
- Heather HancockJackson$39K
- Adam QuinnHattiesburg$29K
- Mark KoskoJackson$27K
- James ShippOxford$21K
- Calvin BrownOlive Branch$15K
- William AshfordMadison$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.